Mybacs

About Mybacs

Mybacs, a Swiss biotechnology company with offices in Zug and Munich, was founded in 2018 by Carl-Philipp von Polheim, Sebastian Wahl, and Adrian Weingart. The company was born from the founders' professional and personal experiences with the importance of gut health, with the initial idea sparked while researching treatments for traveler's diarrhea. Von Polheim brings a background in business administration and finance, having worked in investment banking and for a Berlin startup, while Wahl holds a Master's degree in Pharmacy from ETH Zurich. This combination of business acumen and scientific expertise underpins the company's strategy.

Mybacs operates in the health and wellness market, specifically focusing on the human microbiome. It manufactures and sells synbiotic dietary supplements, which are formulations combining probiotics (beneficial bacteria), prebiotics (food for the bacteria), minerals, and vitamins. The business model is primarily direct-to-consumer (D2C) through its website, utilizing a subscription model for its daily-use products, which promotes customer retention and provides recurring revenue. The company also distributes its products through pharmacies. Its target audience consists of health-conscious individuals seeking to improve their overall well-being by focusing on gut health.

The product line is designed to address various health needs through scientifically-tested formulations. The initial product, Travelbacs, was launched in 2018 and offers regionally-tailored bacterial compositions to prepare the digestive system for travel. This was followed by Dailybacs in 2019, a synbiotic for daily intestinal support, available in formulas for men and women. The portfolio has since expanded to include products targeting specific goals such as weight and metabolism, sleep, energy, focus, skin, and hair. Mybacs differentiates itself by creating high-dose, tailored formulations based on scientific research and maintaining transparency about its ingredients and processes. The company has successfully raised capital, including a Series A round of 5.6 million euros in October 2023, to fund product diversification, international expansion, and team growth.